NCT04072458 - A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 5, 2020

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions

Mantle Cell LymphomaPeripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Follicular LymphomaMarginal Zone LymphomaHodgkin LymphomaWaldenstrom MacroglobulinemiaDLBCL

Interventions

DRUG

L-Bcl-2 antisense oligonucleotide

There will be 2 planned dose levels, 20, and 40 mg/m\^2. Successive cohorts of eligible patients with will be treated with BP1002. BP1002 is given as an intravenous infusion, twice weekly, as 8 doses per 28-day cycle. Cycles may be repeated every 4 weeks.

Trial Locations (5)

10595

New York Medical College / Westchester Medical Center, Valhalla

30912

Georgia Cancer Center, Augusta

37203

Sarah Cannon Research Institute/Tennesee Oncology, Nashville

75390

University of Texas Southwestern Medical Center, Dallas

77030

MD Anderson Cancer Research Center, Houston